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Abstract
Objectives To evaluate the utility of a standardized qualitative
scoring system for treatment response assessment at 18F-FDG
PET-CT in patients undergoing chemoradiotherapy for locally
advanced cervical carcinoma and correlate this with subse-
quent patient outcome.
Methods Ninety-six consecutive patients with locally ad-
vanced cervical carcinoma treated with radical chemoradio-
therapy (CRT) in a single centre between 2011 and 2014
underwent 18F-FDG PET-CT approximately 3 months post-
treatment. Tumour metabolic response was assessed qualita-
tively using a 5-point scale ranging from background level
activity only through to progressive metabolic disease.
Clinical and radiological (MRI pelvis) follow-up was per-
formed in all patients. Progression-free (PFS) and overall sur-
vival (OS) was calculated using the Kaplan-Meier method
(Mantel-Cox log-rank) and correlated with qualitative score
using Chi-squared test.
Results Forty patients (41.7 %) demonstrated complete meta-
bolic response (CMR) on post-treatment PET-CT (Score 1/2)
with 38 patients (95.0 %) remaining disease free after a min-
imum follow-up period of 18 months. Twenty-four patients
(25.0 %) had indeterminate residual uptake (ID, Score 3) at
primary or nodal sites after treatment, of these eight patients
(33.3 %) relapsed on follow-up, including all patients with
residual nodal uptake (n = 4Eleven11 of 17 patients (64.7 %)
with significant residual uptake (partial metabolic response,
PMR, Score 4) subsequently relapsed. In 15 patients (15.6
%) PET-CT demonstrated progressive disease (PD, Score 5)
following treatment. Kaplan-Meier analysis showed a highly
statistically significant difference in PFS and OS between pa-
tients with CMR, indeterminate uptake, PMR and PD (Log-
rank, P < 0.0001). Chi-squared test demonstrated a highly sta-
tistically significant association between increasing qualitative
score and risk of recurrence or death (P < 0.001).
Conclusion Use of a 5-point qualitative scoring system to
assess metabolic response to CRT in locally advanced cervical
carcinoma predicts survival outcome and this prognostic in-
formation may help guide further patient management.
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Introduction
Cervical cancer is the 4th most common malignancy world-
wide in females with more than 527,000 new cases diagnosed
in 2012 [1]. Radical chemoradiotherapy (CRT) is the standard
treatment option for patients with locally advanced disease
[2]. Up to a third of patients develop disease recurrence usu-
ally within the first 2 years after treatment [3]. Use of fluorine-
18 fluorodeoxyglucose (FDG) positron emission
tomography-computed tomography (PET-CT) to assess
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response in the post-therapy setting has been evaluated in a
number of prospective single-centre studies and is found to
predict independently patient outcome [4–7]. Despite the find-
ings of these studies, widespread use of FDG PET-CT in this
setting has yet to enter routine clinical practice and many
centres continue to use a combination of clinical examination
and magnetic resonance imaging (MRI) to evaluate response
to CRT. MRI assessment post-CRT can be challenging with a
risk of false-positive results due to residual post treatment
changes and repeat imaging is required in this circumstance
to avoid unnecessary surgical intervention [8].
FDG PET-CT is now the standard of care for response
assessment in FDG-avid lymphoma and classification using
an internationally recognized 5-point scale (Deauville criteria)
is well established [9]. Similar 5-point qualitative interpreta-
tive criteria for FDG PET-CT response assessment post CRT
have been reported to have substantial inter-reader agreement
and excellent negative predictive value in other clinical sce-
narios including head and neck cancer [10, 11] and lung car-
cinoma [12]. Five-point qualitative interpretation criteria have
not been formally evaluated for response assessment follow-
ing CRT in locally advanced cervical cancer (LACC) to the
best of our knowledge. The purpose of this study was to eval-
uate the utility of a standardized qualitative scoring system for
response assessment at FDG PET-CT in patients undergoing
CRT for LACC in a large-volume tertiary referral centre and
correlate this with subsequent patient outcome.
Materials and methods
Patient cohort
This was a retrospective study performed under a waiver of
informed consent approved by the institutional review board.
Ninety-six female patients with histologically confirmed
LACC treated with curative-intent CRT at a single institution
between February 2011 and April 2014 were included.
Consecutive patients who underwent pre-treatment imaging
and FDG PET-CT following completion of CRT were identi-
fied from an institutional database. Patient characteristics,
staging, treatment, and follow-up details were recorded.
Treatment
During the study period, external beam radiotherapy was de-
livered to the pelvis to a dose of 48 Grays (Gy) in 24 fractions.
Concurrent weekly cisplatin chemotherapy to a dose of 40
mg/m2 was administered during the external beam component
of radiotherapy. Within 10 days of completion, a high-dose
rate intra-cavitary brachytherapy boost was delivered as three
fractions over 3 weeks in the majority of patients. In patients
with issues preventing intra-cavitary treatment or with poor
initial response an external beam boost of 12-18 Gy was given
instead.
PET-CT technique
All FDG PET-CT scans were performed using a Philips
Gemini TF 64 scanner (Philips Healthcare, Netherlands).
Serum blood glucose was checked routinely and imaging
was not performed in patients with a blood glucose level
of > 10 mmol/L. Patients fasted for at least 6 h prior to intra-
venous injection of 400 MBq of 18F-FDG. PET acquisition
from skull base to upper thighs was performed 60 min after
tracer injection. The CT component was performed according
to a standardised protocol (without the use of iodinated con-
trast medium) with the following settings: 140 kV; 80 mAs;
tube rotation time 0.5 s per rotation; pitch 6; section thickness
3.75 mm (to match the PET section thickness). Patients main-
tained normal shallow respiration during the CT acquisition.
Images were reconstructed using a standard OSEM algorithm
with CT for attenuation correction. Both non-attenuation
corrected and attenuation corrected datasets were
reconstructed.
PET-CT interpretation criteria
Metabolic response was assessed qualitatively using a 5-point
scale ranging from background level activity only through to
progressive metabolic disease (Fig. 1). No residual FDG up-
take within primary tumour and nodes compared to surround-
ing background soft tissue activity was scored as 1, consistent
with complete metabolic response (CMR). Focal uptake less
than mediastinal blood pool (MBP) activity was scored as 2,
consistent with likely CMR. Focal uptake greater than MBP,
but less than liver activity was scored as 3 and classified as
indeterminate (ID). Focal uptake greater than liver activity
was scored as 4, consistent with partial metabolic response
(PMR). Focal, intense uptake greater than twice background
hepatic activity or new foci not present on baseline imaging
were scored as 5, progressive disease (PD). All studies were
interpreted by a team of three experienced dual-accredited
radiologists and nuclear medicine physicians with a minimum
of 7 years’ experience of reporting oncologic PET-CT using
specialised software (Advantage Windows Version 4.5, GE
Healthcare, Chalfont St. Giles, UK).
Clinical follow-up
Clinical follow-up of patients with physical examination was
performed 6 weeks following completion of CRT and every 3
months until 2 years post-therapy. MRI scans were performed
at 3 and 12 months. An additional MRI was performed at 6
months if the 3-month scan was indeterminate. Recurrence
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was confirmed histologically or by evidence of progression on
sequential imaging.
Statistical analysis
Times to event were measured from the date of completion of
CRT. Progression-free (PFS) and overall survival (OS) was
calculated using the Kaplan-Meier method (Mantel-Cox log-
rank) and correlated with qualitative score using Chi-squared
test. Correlation between time interval from end of treatment
to imaging and response assessment score was assessed using
Pearson’s correlation coefficient. Statistical analysis was per-
formed using IBM SPSS Statistics for Macintosh (Version 20,
IBM Corp, Armonk, NY, USA).
Results
Patient characteristics
Ninety-six female patients (mean age 47 years, range 24-75
years) with histologically confirmed LACC treated with
curative-intent CRT were included in the study. Patient char-
acteristics are detailed in Table 1.
Time interval of post-therapy imaging and follow-up
All patients had baseline FDG PET-CT pre-treatment and
underwent FDG PET-CT approximately 3 months
following completion of CRT (mean time elapsed be-
tween completion of treatment and response assessment
PET-CT was 98.3 days, range 60-232 days). Of the 96
patients in the study 79 (82.3 %) had a scan 3 months
Table 1 Characteristics of the 96 patients studied
Characteristic Number
Mean age in years (range) 47 (24 -75)
Histology
Squamous 72 (75 %)
Adenocarcinoma 19 (19.8 %)
Adeno/Squamous 3 (3.1 %)
Neuroendocrine 2 (2.1 %)
Stage (FIGO1)
1B1 5 (5.2 %)
1B2 7 (7.3 %)
2A 2 (2.1 %)
2B 65 (67.7 %)
3A 1 (1 %)
3B 7 (7.3 %)
4A 9 (9.4 %)
Nodal disease at baseline
Yes 57 (59.4 %)
No 39 (40.6 %)
Mean primary tumour SUVmax (Range) 14.6 (0 – 41.3)
Treatment Modality
EBRTand intra-cavitary brachytherapy 65 (67.7 %)
EBRTonly (with boost) 31 (32.3 %)
Disease recurrence
Yes 35 (36.5 %)
No 61 (63.5 %)
1 FIGO = International Federation of Gynaecology and Obstetrics
EBRT = External beam radiotherapy
Fig. 1 Five-point qualitative response assessment scoring system for locally advanced cervical carcinoma treated with chemoradiotherapy
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+/- 10 days after treatment. Three patients (3.1 %) had a
scan less than 80 days after treatment (60, 70, and 78
days, respectively), and 14 patients (14.6 %) had a scan
more than 110 days after treatment (of these only one
patient had a scan more than 130 days after treatment, at
230 days). These differences in scheduling were largely
related to scanner and patient availability. All patients
were followed up until death or end of December 2015
(minimum follow-up period of surviving patients 18
months from date of response assessment PET-CT, range
18 – 54 months). There was no statistically significant
correlation between time interval from completion of
CRT to PET-CT and response assessment score
(Pearson’s correlation coefficient, P = 0.32) for patients
who did not subsequently recur (Fig. 2), i.e. there was
no clear cut-off time after which incidence of indetermi-
nate FDG uptake not due to residual tumour diminished.
Classification of PET-CT studies
Of the 96 patients enrolled in the study 40 (41.7 %)
demonstrated CMR on post-treatment PET-CT (Score 1
or 2) with 38 patients (95.0 %) remaining disease free
after a minimum follow-up period of 18 months.
Twenty-four patients (25.0 %) had indeterminate residu-
al primary or nodal uptake (Score 3) after treatment, of
which eight patients (33.3 %) relapsed at follow-up
(Fig. 3), including all patients with residual nodal up-
take (n = 4). Seventeen patients (17.7 %) had significant
residual uptake (Score 4), of which 11 (64.7 %) re-
lapsed. Fifteen patients (15.6 %) demonstrated progres-
sive disease (Score 5) following treatment on the
response-assessment PET-CT (Fig. 4), of which only
one (6.7 %) turned out subsequently to have been false-
ly positive. Table 2 details disease response classifica-
tion by treatment modality and outcome.
Overall performance of PET-CT
The overall sensitivity and specificity of PET-CT in predicting
residual or recurrent disease was 94.3 % (95 % confidence
interval, CI 80.8 – 99.3 %) and 62.3 % (95 % CI 49.0 –
74.4 %), respectively. The positive predictive value was 58.9
% (95 % CI 45.0 – 71.9 %), and the negative predictive value
was 95.0 % (95 % CI 83.1 – 99.4 %). The overall diagnostic
accuracy in this patient cohort was 74 %.
Survival outcomes
Thirty-five patients (36.5 %) developed disease progres-
sion during the follow-up period between the time of the
response assessment PET-CT and death or last patient
encounter at our institution; 21 patients in this group
(60 %) did not receive intra-cavitary brachytherapy. The
mean time to recurrence was 7.3 months (range 2.6 – 38
months). Eight of 24 patients with indeterminate response
(Score 3) on post treatment PET-CT subsequently re-
curred, of which four were successfully salvaged (two
had pelvic exenteration for local relapse, and two had
CRT for localized nodal relapse). The other four patients
were treated with palliative chemotherapy.
Eleven of 17 patients with partial metabolic response
(Score 4) had disease recurrence, of which two were
Fig. 3 PET-CT imaging performed at baseline (top row) and 3 months
post-CRT (bottom row) in a 46-year-old patient with stage 4A disease
shows a bulky primary tumour with distal right ureteric involvement (top
left) and isolated aortocaval nodal disease (top right). Following treatment
there was a goodmetabolic and morphological response to treatment with
only a small residual indeterminate focus of tracer uptake within the
cervix (Score 3, bottom left) and minimal activity within the aortocaval
node (Score 2, bottom right). The patient relapsed 9 months post-
treatment with the development of extensive nodal disease, liver and
lung metastases (not shown). She was treated with palliative
chemotherapy
Fig. 2 Scatter plot demonstrating the relationship between scanning
interval (post-treatment) and response assessment score in patients who
did not recur during the follow-up period
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successfully salvaged with pelvic exenteration. The other nine
patients were treated with palliative chemotherapy.
Twenty-seven patients died during the follow-up period, of
which only one was a non-disease related death (incidental
thromboembolic disease). The average time to death was
16.9 months (range 7.8 – 33.1 months). Kaplan-Meier analy-
sis showed a highly statistically significant difference in PFS
(Fig. 5) and OS (Fig. 6) between patients with Score 1 or 2
(CMR), Score 3 (ID), Score 4 (PMR), and Score 5 (PD)
(Long-rank, P < 0.0001). Chi-squared test demonstrated a
highly statistically significant associated between increasing
qualitative score and risk of recurrence or death (P < 0.001).
Fig. 4 PET-CT imaging
performed 3 months post-CRT in
a 40-year-old patient with stage
2B disease demonstrates CMR in
the pelvis, but a new left humeral
bone metastasis (Score 5, PD).
This was treated with
radiotherapy, but the patient had
progressive metastatic disease
elsewhere and died 18 months
post-initial diagnosis
Table 2 Response classification by treatment modality and outcome
for the 96 patients
Treatment Modality/Outcome Number
EBRT and intra-cavitary brachytherapy (No recurrence) 51
CMR (Score 1 or 2) 33 (64.7 %)
ID (Score 3) 12 (23.5 %)
PMR (Score 4) 5 (9.8 %)
PMD (Score 5) 1 (2.0 %)
EBRT and intra-cavitary brachytherapy (Recurrence) 14
CMR (Score 1 or 2) 1 (7.1 %)
ID (Score 3) 4 (28.6 %)
PMR (Score 4) 3 (21.4 %)
PMD (Score 5) 6 (42.9 %)
EBRT only (No recurrence) 10
CMR (Score 1 or 2) 5 (50 %)
ID (Score 3) 4 (40 %)
PMR (Score 4) 1 (10 %)
PMD (Score 5) 0
EBRT only (Recurrence) 21
CMR (Score 1 or 2) 1 (4.8 %)
ID (Score 3) 4 (19.0 %)
PMR (Score 4) 8 (38.1 %)
PMD (Score 5) 8 (38.1 %)
EBRT = External Beam Radiotherapy
CMR =Complete Metabolic Response
ID = Indeterminate
PMR = Partial Metabolic Response
PMD= Progressive Metabolic Disease
Fig. 5 Kaplan-Meier analysis of progression-free survival (PFS) in
relation to metabolic response on post treatment PET-CT (CMR= Score
1 and 2, ID = Score 3, PMR = Score 4, PD = Score 5)
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Discussion
Use of FDGPET-CT to assess post-CRT response in LACChas
been evaluated in a number of prospective single centre studies
and found independently to predict patient outcome [4–7].
Additional key roles of FDG PET-CT are to flag patients with
loco-regional treatment failure potentially suitable for salvage
therapy and to identify patients who have developed unsuspect-
ed asymptomatic distant metastatic disease not detected on clin-
ical examination. Despite these data, post-therapy PET-CT is
not yet routinely recommended in LACC patients who have
undergone CRT [13].
The largest prospective study evaluated 238 patients with
LACC and reported a 23 % relapse rate in patients with CMR
[7]. The relapse rate in CMR patients in other studies ranged
from 10-21 % [5, 6] compared to 5 % in our patient cohort.
Previous studies have not used a standardized qualitative scor-
ing system and have performed PET-CTat varying time points
post-treatment, which may in part explain this difference. One
of the groups have recently reported long-term 5-year survival
outcomes in their prospective patient cohort and confirmed
that CMR on post-treatment PET-CT remains a powerful pre-
dictor of survival with a 97 % 5-year overall and 86 %
progression-free survival rate [14]. Few published studies
have reported the diagnostic accuracy of PET-CT in this clin-
ical scenario. The NPV in our series (95 %) is comparable to
that reported (97 %) in a large series of 276 cervical cancer
patients undergoing post-treatment PET-CT although the me-
dian time between treatment and post-therapy scan was 24
months in their study [15].
A potential issue with the use of FDG PET-CT post-CRT is
the lack of specificity of tracer uptake as evidenced by the low
specificity (62.3 %) in our series. In particular, there is a po-
tential for false-positive uptake in some patients, with partial
metabolic response as a result of persistent post radiation in-
flammation. The largest study of LACC patients reported that
only 26 patients (65 %) with PMR on response-assessment
PET-CT had biopsy proven residual disease [7]. In our study
the degree of residual uptake in the primary tumour was asso-
ciated with an increasing risk of relapse: however, a signifi-
cant number of patients with Score 3 (16 patients, 67.7 %) and
Score 4 (six patients, 35.3 %) did not relapse during the
follow-up period, which explains the sub-optimal PPV (61.1
%). Interestingly, all patients with residual nodal uptake great-
er than background liver activity went on to relapse in our
study. There was no statistically significant correlation be-
tween the time interval from end of treatment to PET-CT im-
aging and response assessment score in patients who did not
subsequently recur. The optimal timing of post-treatment
PET-CT response assessment remains uncertain with one
group advocating a longer delay of 6 months before imaging
to reduce the incidence of false positive inflammatory activity
albeit with a small risk of missing early asymptomatic recur-
rence [5, 14]. A number of different groups have employed a
similar time interval to ourselves ranging between 8 and 16
weeks [4, 6–16]. More recently, a number of small studies
have evaluated the use of early response assessment with
PET-CT either during or within a month of completing CRT
to predict relapse in LACC patients with promising results,
but no clear consensus [17–19]. The high negative predictive
value in the current study (95%) suggests 3 months may be an
acceptable time point when combined with objective assess-
ment although this should be confirmed in a larger prospective
multi-centre trial.
How best to manage equivocal or indeterminate response
remains unclear and requires further study. Several groups
have reported the use of early repeat PET-CT imaging after
an initial indeterminate result as an alternative to salvage sur-
gery in head and neck cancer patients [20–23], but the safety
of this strategy has not been reported in LACC. Since the
majority of LACC patients routinely undergo MRI post-treat-
ment, a combined standardized MRI and PET-CT response
assessment scoring systemmight help increase specificity par-
ticularly if this were to encompass diffusion weighted MRI
where an increase in apparent diffusion coefficient following
treatment has been reported to correlate well with complete
response [24, 25]. This warrants further evaluation in a future
study.
There was a lower incidence of disease relapse in patients
who received high dose rate intra-cavitary brachytherapy (14
of 61 patients, 23.0 %) compared to those who had EBRT
boost (21 of 31 patients, 67.7 %). This is not surprising since
the latter group generally had more advanced disease, the
Fig. 6 Kaplan-Meier analysis of overall survival (OS) in relation to
metabolic response on post treatment PET-CT (CMR= Score 1 and 2,
ID = Score 3, PMR = Score 4, PD = Score 5)
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radiation dose received without brachytherapy is generally
lower and it is well recognised that treatment without brachy-
therapy is associated with lower survival rates [26, 27].
Despite the relatively low PPV in this series, there was clear
evidence of persisting disease or disease progression on the
post treatment scan in 15 patients (15.6 %) which provided
additional information and helped guide appropriate further
management. One patient in this group had new pelvic nodal
uptake interpreted as disease progression which subsequently
resolved spontaneously with no evidence of disease relapse
during the follow-up period. This is likely to have been due to
treatment related inflammation.
A recent large study of 362 patients with head and
neck cancer reported the safety and cost-effectiveness of
a less intensive clinical follow-up strategy in patients with
CMR on a 3-month post-treatment FDG PET-CT with
reduction in frequency of follow-up from 3 to 6 months
with no apparent clinical detriment and reduced costs [28].
A similar study in patients with LACC has not been re-
ported and this warrants further evaluation to assess the
safety and validity of risk-adapted follow-up based on
post-treatment PET-CT response.
There are a number of limitations to this study, includ-
ing the single institution and retrospective nature, relatively
small cohort size, and not all patients received the same
treatment, with some patients not suitable for high-dose
brachytherapy. There is growing evidence of the superior
utility of objective 5-point scoring systems for PET-CT
assessment of treatment response in a variety of tumour
types [9–11]. Despite the stated limitations, the potential
superior efficacy of a standardized 5-point scoring system
for response assessment PET-CT in patients with LACC
has been demonstrated. This requires validation in a larger
prospective multi-centre study, which could be designed to
guide a less invasive and resource-intensive follow-up
strategy for patients demonstrating CMR.
Conclusions
Use of a 5-point qualitative scoring system to assess metabolic
response to CRT in locally advanced cervical carcinoma pre-
dicts survival outcome and this prognostic information may
help guide further patient management.
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